Literature DB >> 1867175

Antineutrophil cytoplasmic autoantibody-associated diseases: a rheumatologist's perspective.

W L Gross1, W H Schmitt, E Csernok.   

Abstract

Autoantibodies against neutrophil cytoplasmic antigens (ANCA) produce two major immunofluorescence (IF) patterns on ethanol-fixed granulocytes: the "classical" (centrally accentuated) C-ANCA, associated with Wegener's granulomatosis (WG), and P-ANCA (perinuclear), which mainly occur in renal vasculitis. Rheumatic manifestations are an important clinical finding in systemic vasculitis, often preceding a fulminant course and sometimes imitating various rheumatic disorders. We analyzed the incidence of ANCA in rheumatic patients and looked for the frequency of rheumatic symptoms in systemic vasculitis. In WG (n = 186), we found rheumatic symptoms in 55% (myalgia, 45%; arthritis, 21%); in 90%, rheumatic complaints were associated with active vasculitis. In 730 patients with various rheumatic conditions (eg, 268 rheumatoid arthritis, 130 systemic lupus erythematosis [SLE], 32 sharp-S, 50 ankylosing spondylitis, 43 systemic sclerosis) no C-ANCA were found. On the contrary, the P-ANCA pattern was seen in seven of 62 giant cell arteritis, five of 27 Felty's/Still's syndrome, and four of 130 SLE patients in addition to renal vasculitis (21/74). We demonstrated that 95% of C-ANCA-positive sera react with proteinase 3 (PR3 or myeloblastin). Using monoclonal antibodies, we showed that PR3 is expressed on the plasma membrane of neutrophil granulocytes and monocytes; thus, PR3 autoantigens are accessible for circulating antibodies. The detection of ANCA in sera from vasculitis and other rheumatic diseases is of immunodiagnostic value and provides new insight in the pathogenesis of systemic vasculitides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867175     DOI: 10.1016/s0272-6386(12)80876-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

1.  Wegener granulomatosis involving the pterygopalatine fossa: an unusual case of trigeminal neuropathy.

Authors:  Kathlyn Marsot-Dupuch; Sebastien Clement De Givry; Michel Ouayoun
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

2.  Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.

Authors:  H Chikazawa; K Nishiya; A Matsumori; K Hashimoto
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

3.  Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features.

Authors:  K Nishiya; H Chikazawa; S Nishimura; N Hisakawa; K Hashimoto
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

4.  Mononeuritis multiplex as a presenting feature of Wegener granulomatosis: a case report.

Authors:  R Peshin; D O'Gradaigh
Journal:  Clin Rheumatol       Date:  2006-11-18       Impact factor: 2.980

5.  Antineutrophil cytoplasmic antibodies in systemic sclerosis.

Authors:  S Kiraz; H Simsek; I Ertenli; M Benekli; A Kadayifci
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

6.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

7.  Long-term clinical course in acute crescentic glomerulonephritis.

Authors:  D Bach; K Hauser; B Grabensee
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

8.  Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  J A Savige; L Chang; D Wilson; R R Buchanan
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 9.  Classification and management of necrotising vasculitides.

Authors:  L Guillevin; F Lhote
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

10.  Microscopic polyangiitis in systemic sclerosis.

Authors:  Hiroshi Hashimoto
Journal:  Int J Rheumatol       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.